LOBEF (Lobe Sciences) Notes Receivable: $0.00 Mil (As of Feb. 2026)


What is Lobe Sciences Notes Receivable?

Lobe Sciences LOBEF +12.45% Notes Receivable is $0.00 Mil as of Feb. 2026. The stock has 2 warning signs investors should review.

Lobe Sciences's Notes Receivable for the quarter that ended in Feb. 2026 was $0.00 Mil.

Lobe Sciences Notes Receivable Historical Data

* Premium members only.

The historical data trend for Lobe Sciences's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lobe Sciences Notes Receivable Chart

Lobe Sciences Annual Data
Trend Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lobe Sciences Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lobe Sciences Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Lobe Sciences (LOBEF) has a Notes Receivable of $0.00 Mil as of Feb. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Lobe Sciences and its competitors.
Is Lobe Sciences' Notes Receivable too high?
Lobe Sciences' current Notes Receivable is $0.00 Mil.
How does Lobe Sciences' Notes Receivable compare to VRTX and REGN?
Lobe Sciences' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Lobe Sciences and its competitors. Lobe Sciences's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (LOBEF) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Lobe Sciences (LOBEF), the current Notes Receivable is $0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lobe Sciences Business Description

Other Exchanges LOBE:GermanyLOBE:Canada
Address 1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.